As authors note, the interesting difference between their obtained results and previous studies could reside in the administration rout of desmopressin (sublingual vs. intranasal). It is also noteworthy that besides the administration rout, Pricop et al. study was different from previous trials in using a higher dose of desmopressin (60 and 120 μg vs. 40 μg) and different type of NSAID (ketorolac vs. diclofenac). Therefore, with these assumptions, the difference in results can be better explained. Editor,
Editor,
We read the study conducted by Pricop et al. entitled "Sublingual desmopressin is efficient and safe in the therapy of lithiasic renal colic" and wish to offer some comments [1] . Authors have reached interesting outcomes, and we appreciate their efforts for sharing their results. Authors indicate that sublingual desmopressin can be as effective as nonsteroidal anti-inflammatory drugs (NSAIDs) in renal colic pain management. They also demonstrate an additive analgesic effect for the combination of sublingual desmopressin and NSIADs in pain reduction. According to previous studies, authors discussed in their article that the combination of intranasal desmopressin with NSAIDs or opioids does not add any benefit as an adjunct for pain management. For the first time in 2016, we conducted a meta-analysis on ten studies in order to compare the efficacy of intranasal desmopressin with NSAIDs and opioids in management of pain in nephrolithiasis [2] . We observed that intranasal desmopressin is less effective in pain reduction in comparison with both NSIADs and opioids. We also demonstrated that intranasal desmopressin does not provide any benefit in combination with NSAIDs for pain control. However, our obtained results indicated that intranasal desmopressin in combination with opioids significantly reduces need for rescue treatment in patients. Therefore, it was concluded that intranasal desmopressin could be used as an adjunctive treatment with opioids to improve pain management.
